Just Biotherapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Just Biotherapeutics, Inc.
Evotec Stock Buoyed By Takeda Alliance
Evotec and Takeda aim to develop at least five drug candidates by leveraging the German group’s discovery platform.
Evotec Had Strong H1, Foresees Dual Track Growth After Entering Biologics Space
Evotec upped its full-year guidance after a strong second quarter that saw an important strategic expansion into the biologics space through the acquisition of Just Biotherapeutics Inc.
Deal Watch: Ireland's Amryt Acquires Aegerion
European firms Amryt and Evotec have signed agreements to acquire two companies based across the Atlantic – Aegerion and Just Biotherapeutics, respectively.
Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Hangzhou Just Biotherapeutics, Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.